Publications by authors named "Ronald Christopher"

Claim this Profile
S
Safety, Pharmacokinetics, and Cardiodynamics of CMS121, a Novel Small Molecule Fisetin Derivative with Neuroprotective Properties, in Phase 1 Healthy Adult Volunteers.
Pamela Maher, Ronald Christopher, Rebecca Evans, William Raschke

medRxiv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of APD371: Identification of a Highly Potent and Selective CB Agonist for the Treatment of Chronic Pain.
Sangdon Han, Lars Thoresen, Jae-Kyu Jung, Xiuwen Zhu, Jayant Thatte, Ronald Christopher

ACS Med Chem Lett· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
Laurent Peyrin-Biroulet, Ronald Christopher, Dominic Behan, Cheryl Lassen

Autoimmun Rev· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Tolerability of Lorcaserin in Special Populations: Elderly Patients and Patients with Renal or Hepatic Impairment.
Ronald J Christopher, Michael E Morgan, Yong Tang, Christen Anderson, Matilde Sanchez

Clin Ther· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single- and Multiple-dose Pharmacokinetics of a Lorcaserin Extended-release Tablet.
Ronald Christopher, Mike Morgan, Jim Ferry, Bhaskar Rege, Yong Tang

Clin Ther· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.
Daniel J Buzard, Sun Hee Kim, Luis Lopez, Andrew Kawasaki, Xiuwen Zhu, Ronald J Christopher

ACS Med Chem Lett· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists.
Daniel J Buzard, Luis Lopez, Jeanne Moody, Andrew Kawasaki, Thomas O Schrader, Ronald J Christopher

ACS Med Chem Lett· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes.
Ronald Christopher, Aziz Karim

Expert Rev Clin Pharmacol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Bumsup Lee, Lihong Shi, Daniel B Kassel, Tomoko Asakawa, Koji Takeuchi, Ronald J Christopher

Eur J Pharmacol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Paul Covington, Ronald Christopher, Michael Davenport, Penny Fleck, Qais A Mekki

Clin Ther· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Ronald Christopher, Paul Covington, Michael Davenport, Penny Fleck, Qais A Mekki

Clin Ther· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis